Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Volaris Reports December 2023 Traffic Results: 85% Load Factor
-
Micron Solutions, Inc. Announces Completion of Stock Splits
-
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
NuLegacy Suspends 2024 Exploration Program
-
Costco Wholesale Corporation Reports December Sales Results
-
DoubleDown Interactive to Participate in iAccess Alpha Virtual MicroCap Conference on January 9th and 10th
-
Enact to Host Fourth Quarter 2023 Earnings Call February 7th
-
ETC’s Aerospace Segment Awarded $12.4 Million in Contracts
-
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lym
-
Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System
-
Costco Wholesale Corporation Reports December Sales Results
-
DoubleDown Interactive to Participate in iAccess Alpha Virtual MicroCap Conference on January 9th and 10th
-
Compass Diversified Declares Fourth Quarter 2023 Distributions on Common and Series A, B and C Preferred Shares
-
Voyager Therapeutics Announces Proposed Public Offering
-
Candelaria Announces Change in Chief Financial Officer
-
National Bank Holdings Corporation Announces Date for 2023 Fourth Quarter Earnings Release
-
CTO Realty Growth Announces 2023 Transaction and Leasing Activity and Provides Share Repurchase Update
-
Alpine Income Property Trust Announces 2023 Transaction Activity and Provides Corporate Update
-
Park Aerospace Corp. Announces Date of Third Quarter Earnings Release and Conference Call
-
PennantPark Investment Corporation Schedules Earnings Release of First Fiscal Quarter 2024 Results
-
PennantPark Floating Rate Capital Ltd. Schedules Earnings Release of First Fiscal Quarter 2024 Results
-
Great Lakes Provides Update on Empire Wind I and II Contracts
-
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
-
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
-
Kura Sushi USA Announces Fiscal First Quarter 2024 Financial Results
-
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
-
Brookline Bancorp, Inc. Announces Fourth Quarter 2023 Earnings Release Date and Conference Call
-
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
-
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
-
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
-
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
-
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
-
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
-
Trio Petroleum Corp Announces the Restart of the McCool Ranch Oil Field
-
Port of Oakland, Parsons and Partners Launch New App to Improve Port Operations
-
Joseph Guiliano appointed Chief IP Officer of Adeia
-
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
-
Aeries Technology to Participate at the 26th Annual ICR Conference
-
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
-
Lavoro to Participate in the 2024 ICR Conference on January 9, 2024
-
QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business
-
Robinhood Markets, Inc. to Announce Fourth Quarter and Full Year 2023 Results on February 13, 2024
-
Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares
-
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
-
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
-
Kymera Therapeutics Announces Proposed Public Offering
-
LGI Homes Delivers Annual Home Closings and Sets Date for Fourth Quarter and 2023 Year End Earnings Conference Call
-
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
-
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
-
Brookfield Renewable Announces Updated Green Financing Framework
